Antibiotic

$75+ Billion Probiotics Market - Global Forecast to 2027: Increasing Use of Probiotics as an Alternative to Antibiotics - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 4, 2021
Retail, Health, Fitness & Nutrition, Agriculture, Natural Resources, Food, Beverage, Bacteriology, Digestive system, Probiotic, Antibiotic, Biotic

The increasing use of yeast strain in animal feed & functional food and the rising use of probiotics as an alternative to antibiotics are the major drivers for the growth of this segment.

Key Points: 
  • The increasing use of yeast strain in animal feed & functional food and the rising use of probiotics as an alternative to antibiotics are the major drivers for the growth of this segment.
  • Dry probiotics offer advantages, such as better handling & transport, ease of use, affordability, and the ability to avoid costly formulation mistakes.\nBased on sales channel, the probiotics market is segmented into offline and online sales.
  • The offline sales segment is expected to command the largest share of the overall probiotics market in 2020.
  • The animal probiotics sector has witnessed significant growth due to the growing pressure regarding reducing the use of antibiotics in feed.

Recce Pharmaceuticals Announces Positive Data on Bactericidal Activity of RECCE® 327 Against All Six ESKAPE Pathogens

Retrieved on: 
Tuesday, May 4, 2021
Health sciences, Medicine, Health, ESKAPE, Medical terminology, Antibiotic, XC2, Antimicrobial resistance, Infection, Drug resistance, The Pew Charitable Trusts

\xe2\x80\x9cAntimicrobial resistance is one of the most urgent threats to global public health with the suite of ESKAPE pathogens posing a significant threat due to their virulence and rapid development of drug-resistance.

Key Points: 
  • \xe2\x80\x9cAntimicrobial resistance is one of the most urgent threats to global public health with the suite of ESKAPE pathogens posing a significant threat due to their virulence and rapid development of drug-resistance.
  • The slight variation (+/-) between one experiment to the next is likely due to small variance in the sensitivity of the instruments used in detection.
  • Further to this designation, RECCE\xc2\xae 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the only synthetic polymer and sepsis drug candidate in development.\nRecce wholly owns its automated manufacturing, ready to support first-in-human clinical trials.
  • Recce\xe2\x80\x99s anti-infective pipeline seeks to exploit the unique capabilities of RECCE\xc2\xae technologies targeting synergistic, unmet medical needs.\n"

ContraFect Announces Issuance of Composition of Matter Patent for CF-370 by the United States Patent and Trademark Office

Retrieved on: 
Monday, May 3, 2021
Bacteriology, Medical specialties, Microbiology, Lysin, Staining, Branches of biology, Gram-negative bacteria, Antibiotic, Bacteria

10,988,520 (the \xe2\x80\x98520 patent), on April 27, 2021 for CF-370, the company\xe2\x80\x99s second potential therapeutic product candidate.

Key Points: 
  • 10,988,520 (the \xe2\x80\x98520 patent), on April 27, 2021 for CF-370, the company\xe2\x80\x99s second potential therapeutic product candidate.
  • Gram-negative bacteria have an outer membrane that makes them more resistant to antibiotics.
  • By killing targeted bacteria upon contact, lysins are fundamentally different than conventional antibiotics.\n"With the issuance of this important patent, we continue expanding ContraFect\xe2\x80\x99s strong intellectual property estate covering this new class of antibacterial drugs.
  • CF-370 has been engineered to bypass the outer membrane of the bacteria and to enable potent activity in human serum.

Avivagen Announces Recurring Order for OxC-betaTM Livestock

Retrieved on: 
Monday, May 3, 2021
Biotechnology, Agriculture, Health, Natural Resources, Meat industry, Antibiotic, Livestock, Forward-looking statement, Articles

Through support of immune function the technology provides a non-antibiotic means of promoting health and growth.

Key Points: 
  • Through support of immune function the technology provides a non-antibiotic means of promoting health and growth.
  • OxC-beta\xe2\x84\xa2 Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds.
  • Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates.
  • Readers are referred to the risk factors associated with the business of Avivagen set out in Avivagen\xe2\x80\x99s most recent management\xe2\x80\x99s discussion and analysis of financial condition available at www.SEDAR.com .

Spero Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on Thursday, May 6, 2021

Retrieved on: 
Thursday, April 29, 2021
Health sciences, Articles, Health, Prodrugs, Tebipenem, Carbapenem, Antimicrobial resistance, Antibiotic

b'CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.\xc2\xa0(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on May 6, 2021 at 4:30 p.m.

Key Points: 
  • b'CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.\xc2\xa0(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on May 6, 2021 at 4:30 p.m.
  • ET to report its first quarter 2021 financial results and provide an update on its business and pipeline.\nTo access the call please dial 877-705-6003 (domestic) or 201-493-6725 (international) and refer to conference ID 13718122.
  • The audio webcast can be accessed under \xe2\x80\x9cEvents and Presentations\xe2\x80\x9d in the Investor and Media section of the Company\xe2\x80\x99s website at www.sperotherapeutics.com .
  • The archived webcast will also be available on Spero\xe2\x80\x99s website for 30 days following the call.\nSpero Therapeutics, Inc.\xc2\xa0is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.\nSpero\xe2\x80\x99s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP).

DEINOVE, ESPCI Paris and INRAE awarded grant following the call for proposals of the French “Antibiotic resistance” Priority Research Program

Retrieved on: 
Thursday, April 29, 2021
Medical specialties, Health sciences, Medicine, Antibiotic-resistant bacteria, Evolutionary biology, Pharmaceuticals policy, Veterinary medicine, Immunology, Clostridioides difficile, Antimicrobial, Antibiotic, Drug resistance

The evaluations reached the same conclusion: the microfluidic technology developed by DEINOVE is considered by the scientific and industrial community as a major asset for the screening and identification of new therapeutic solutions from bacterial biodiversity.\nAntibiotic resistance has become a major public health emergency that is now mobilizing the entire international community5, and of course France.

Key Points: 
  • The evaluations reached the same conclusion: the microfluidic technology developed by DEINOVE is considered by the scientific and industrial community as a major asset for the screening and identification of new therapeutic solutions from bacterial biodiversity.\nAntibiotic resistance has become a major public health emergency that is now mobilizing the entire international community5, and of course France.
  • By revealing the metabolic potential of rare bacteria or still classified as uncultivable, it tackles a global health and economic challenge: antimicrobial resistance.
  • Today, DEINOVE is conducting several development programs, of which its first antibiotic candidate is currently evaluated in a Phase II clinical trial in severe Clostridioides difficile infections, one of the world\xe2\x80\x99s first emergencies.
  • It aims to support \xe2\x80\x9cvery ambitious, structuring, long-term (3 to 6 years) research projects favoring interdisciplinarity and contributing to the emergence of synergies between different types of research (fundamental, environmental, clinical, translational), with the goal of stimulating and supporting the emergence of diagnostic, preventive and therapeutic innovations, and ultimately leading to a better use of antibiotics\xe2\x80\x9d.\n'

Specific Diagnostics Awarded Grant by the Department of Defense (DoD) to use Reveal for the Rapid Determination of the Antimicrobial Effectiveness of Bacteriophage

Retrieved on: 
Thursday, April 29, 2021
Public policy, Government, Health, Healthcare reform, Infectious diseases, Other Policy Issues, Pharmaceutical, Biotechnology, Health sciences, Health, Articles, Pharmaceuticals policy, Veterinary medicine, Antimicrobial resistance, Evolutionary biology, Drug resistance, Phage therapy, Antibiotic, Bacteriophage

With bacteria evolving resistance to antibiotics, driven in part by overuse, bacteriophage therapy represents a distinct and promising alternative to antibiotic therapy.\n\xe2\x80\x9cIn the age of antibiotic resistance, alternatives to antibiotics are increasingly needed,\xe2\x80\x9d said Dr. Paul A. Rhodes, Specific\xe2\x80\x99s CEO.

Key Points: 
  • With bacteria evolving resistance to antibiotics, driven in part by overuse, bacteriophage therapy represents a distinct and promising alternative to antibiotic therapy.\n\xe2\x80\x9cIn the age of antibiotic resistance, alternatives to antibiotics are increasingly needed,\xe2\x80\x9d said Dr. Paul A. Rhodes, Specific\xe2\x80\x99s CEO.
  • Its first commercial application applies this fundamental new capability to the rapid determination of antimicrobial susceptibility directly from positive blood cultures, as well as isolate dilutions.
  • Specific is based in Mountain View, CA.
  • For press inquiries, please contact: Jeff Holman, [email protected]\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210429005732/en/\n'

Melinta Therapeutics and Hikma Sign Exclusive Licensing Agreement for Two Novel Anti-Infectives for the Middle East and North Africa Region

Retrieved on: 
Thursday, April 29, 2021
Biotechnology, Infectious diseases, Other Health, Health, Pharmaceutical, Chemical compounds, Organic compounds, Chemistry, Azetidines, Chloroarenes, Delafloxacin, Pyridines, Antibiotic, XC2, Medication, Melinta Therapeutics, Hikma, MELINTA THERAPEUTICS, HIKMA

This extends Hikma\xe2\x80\x99s existing partnership with Melinta for their intravenous and oral formulations of Baxdela\xc2\xae (delafloxacin), a novel antibiotic product.

Key Points: 
  • This extends Hikma\xe2\x80\x99s existing partnership with Melinta for their intravenous and oral formulations of Baxdela\xc2\xae (delafloxacin), a novel antibiotic product.
  • \xe2\x80\x9cAs one of the leading suppliers in the region, it is our responsibility to equip doctors with the latest and most innovative developments to treat their patients.
  • Visit www.melinta.com for more information.\nHikma helps put better health within reach every day for millions of people around the world.
  • For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them.

New PhRMA Report Shows Nearly 90 Medicines in Development to Fight Drug-Resistant Infections, but Future Pipeline Remains Challenging

Retrieved on: 
Thursday, April 29, 2021
Health sciences, Articles, Pharmaceuticals policy, Life sciences, Veterinary medicine, Evolutionary biology, Antimicrobial resistance, Antimicrobial, Antibiotic, Medication

Today, this progress is being threatened by a health crisis on the rise: antimicrobial resistance (AMR).

Key Points: 
  • Today, this progress is being threatened by a health crisis on the rise: antimicrobial resistance (AMR).
  • Developing new antimicrobial medicines can take anywhere from 10-20.5 years and $568-$700 million to develop a single new medicine.
  • In fact, among investigational medicines in preclinical development for existing classes of antibiotics just one in 15 will ultimately be approved and reach patients.
  • Those new treatments could be the ones we need to address the next pandemic, or the next superbug.

Rocket Pharmaceuticals Announces Upcoming Clinical Data Presentations at the 24th Annual Meeting of the American Society of Gene and Cell Therapy

Retrieved on: 
Tuesday, April 27, 2021
Research, Genetics, Clinical trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Antibiotic, Adeno-associated virus, Branches of biology, Leukocyte Adhesion Deficiency-I, Pyruvate Kinase Deficiency, Fanconi Anemia, Rocket Pharmaceuticals, Inc., LEUKOCYTE ADHESION DEFICIENCY-I, PYRUVATE KINASE DEFICIENCY, FANCONI ANEMIA, ROCKET PHARMACEUTICALS, INC.

During infancy, they suffer from recurrent life-threatening bacterial and fungal infections that respond poorly to antibiotics and require frequent hospitalizations.

Key Points: 
  • During infancy, they suffer from recurrent life-threatening bacterial and fungal infections that respond poorly to antibiotics and require frequent hospitalizations.
  • Children who survive infancy experience recurrent severe infections including pneumonia, gingival ulcers, necrotic skin ulcers, and septicemia.
  • Mutations in the PKLR gene result in increased red cell destruction and the disorder ranges from mild to life-threatening anemia.
  • Rocket\xe2\x80\x99s first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition.